Janusz Jankowski research projects
CRUK/05/006: ASPECT: Aspirin esomeprazole chemoprevention trialFunding period: 01 January 2005 to 31 December 2014
Funding scheme: Phase III Clinical Trial Grants
Funding committee: Clinical Trials Awards and Advisory Committee
In the UK oesophageal adenocarcinoma causes over 5% of cancer related mortality and yet it has only 1.4% of the NCRI budget spent on it. Prevention of cancer is a vital strand of the national plans for the NHS yet only 2% of the NCRI budget is spent on this compared with 9% in the NCI USA.
This is one of the World's largest upper GI chemoprevention trials and aims primarily to prevent conversion to cancer in patients with the pre-malignant lesion, Barrett's metaplasia. The interventions evaluated are high versus standard dose proton pump inhibitor therapy and aspirin versus no aspirin. We will also assess whether aspirin reduces all cause mortality.
How the results will be used
Our trial provides useful secondary outcomes exploiting a unique collection of thousands of patients with combined serial tissue and blood samples together with detailed clinico-pathological information. Our trial represents a real opportunity for the UK to grasp the initiative and produce robust generalisable data for the management and improved understanding of oesophageal adenocarcinoma. Our trial will also represent a net saving to the NHS as all the patients enrolled would have been taking lacid suppression medication and now this will be provided free to a net saving of £15,000,000.
Browse similar research
- Prevention: Chemoprevention
- Prevention: Complementary & alternative approaches - prevention
- Oesophageal cancer